Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FER | P16591 | 6/20 | 0.57 |
| ▸ | SYK | P43405 | 14/20 | 0.56 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.56 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15081537 | 1.00 | FER (0.57) | FERSYKMAPK3MAPK1KCNH2 | |
| SCHEMBL16215548 | 1.00 | FER (0.57) | FERSYKMAPK3MAPK1KCNH2 | |
| SCHEMBL16171097 | 1.00 | FER (0.57) | FERSYKMAPK3MAPK1KCNH2 | |
| SCHEMBL16164685 | 0.90 | FER (0.55) | FERSYKMAPK3MAPK1KCNH2 | |
| SCHEMBL14910022 | 0.89 | SYK (0.58) | FERSYKMAPK3MAPK1KCNH2 | |
| SCHEMBL14928662 | 0.89 | FER (0.54) | FERSYKMAPK3MAPK1KCNH2 | |
| SCHEMBL10250818 | 0.89 | SYK (0.58) | FERSYKMAPK3MAPK1KCNH2 | |
| SCHEMBL3387186 | 0.89 | SYK (0.58) | FERSYKMAPK3MAPK1KCNH2 | |
| SCHEMBL14910975 | 0.89 | FER (0.54) | FERSYKMAPK3MAPK1KCNH2 | |
| SCHEMBL9106129 | 0.89 | SYK (0.56) | FERSYKMAPK3MAPK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309225-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309225-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, BTK, NOX4 | FER 441/4885SYK 1/4885MAPK3 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.